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Aims Advanced cardiac disease, entailing more hypertrophy, ﬁbrosis, scarring, dilatation and conduction delays, poses the
question of whether deﬁbrillation thresholds (DFTs) increase as left ventricular ejection fraction (LVEF) decreases.
This question has been approached indirectly or insufﬁciently in previous studies. In this study we add and expand
on our previous work, stratifying DFT for various LVEF ranges.
Methods
and results
ThisretrospectiveanalysisincludedDFTdatafromthreeacute,multicentre,randomizedstudiesthatincluded230ICD/
CRT-D patients. All DFTs were obtained with the SVC coil turned ON and with pulse-width optimized waveforms
based on a 3.5 ms membrane time constant. As the LVEF decreased, DFT estimates increased from 395.2+115 V
for LVEF   46% to 425.8+117.6 V for LVEF   25%. However, these changes in DFT estimates were very minor
and not statistically signiﬁcant. Only 3% of the patients in this population had an elevated DFT of .20 J.
Conclusion This analysis shows that over a very broad range of LVEF, DFT changes minimally (approximately 1 J), if at all. Our
results are consistent with previous studies that demonstrated no difference in the DFT estimates: (a) between
patient groups receiving ICD (typically higher LVEF) vs. CRT-D (typically lower LVEF) and (b) between patient
groups receiving a device for primary prevention indications (typically lower LVEF) vs. secondary prevention indi-
cations (typically higher LVEF).
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Deﬁbrillation threshold † Implantable cardioverter deﬁbrillator † Ejection fraction
Introduction
Implantation of implantable cardioverter deﬁbrillators (ICDs) and
cardiac resynchronization therapy-deﬁbrillators (CRT-Ds) has sig-
niﬁcantly increased after the positive results of some landmark
primary prevention trials showing the efﬁcacy of ICD therapy in
reducing mortality.
1–3 Deﬁbrillation threshold (DFT) testing at
implant is routinely done to ensure that the ICDs/CRT-Ds deliver
appropriate amounts of energy and are functioning appropriately.
The left ventricular ejection fraction (LVEF) of ICD patients
implanted for either primary or secondary prevention can range
from normal or near-normal (.45%) to severely impaired
(,25%). Typically, patients with a low LVEF also have underlying
cardiac disease that has progressed to an advanced degree.
Among various other clinical parameters, depressed LVEF has
been shown to be a potential predictor of high DFTs in patients
implanted with unipolar or bipolar deﬁbrillation systems.
4–8
While clinical predictors of high DFTs have been extensively
studied in patients receiving ICDs/CRT-Ds, stratiﬁcation of DFTs
by LVEF, one of the most commonly used indices for cardiac
impairment, has never been done before. Accordingly, this analysis
was undertaken to assess the change in DFT estimates as the LVEF
goes from being normal to impaired in patients who are implanted
with left-sided, active pectoral deﬁbrillation lead systems.
Methods
This retrospective analysis included data from three different multicen-
tre, prospective, randomized studies that were reviewed and approved
by the appropriate Human Research Ethical Committees of each of the
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9–11 Study-speciﬁc objectives, inclusion,
and exclusion criteria for all the three studies are listed in Table 1.
Patients were enrolled by the study site after appropriate informed
consent was obtained. The patient population consisted of 230
patients who were implanted with any FDA-approved Atlas
w, Epic
w,
Current
w, and Promote
w ICDs/CRT-Ds and a compatible dual-coil
deﬁbrillation lead system. All patients who met the inclusion criteria
in these three studies and underwent DFT testing using SVC coil
turned ON were included in this analysis.
Deﬁbrillation threshold testing
Two of three studies required the use of a binary search protocol and
72% of the data contributing to this analysis came from those
studies.
9,10 One of the three studies required the use of a binary
search protocol guided by upper limit of vulnerability and 28% of
the data contributing to this analysis came from that study.
11 The deﬁ-
brillation waveform for all patients was programmed to the optimal
pulse width settings based on a theoretical 3.5 ms membrane time
constant using a commercially available chart of optimal deﬁbrillation
pulse width (Phase 1/Phase 2) durations.
12 The RV coil was pro-
grammed as the anode for the ﬁrst phase and the SVC coil was
always turned on. Ventricular ﬁbrillation was induced by T-wave
shock, burst-pacing, or ‘DC (direct current) Fibber’ through the
ICDs. For all the methods, DFT estimate was established only after
observation of a failed shock.
Analysis
DFT estimates were stratiﬁed into four different LVEF groups ( 25%,
26–35%, 36–45%, and  46%). A linear model in which the LVEF
group is treated as a factor was used to analyse the data. A
P-value , 0.05 was considered statistically signiﬁcant.
Results
There were 230 patients included in this analysis (Table 2). The
average age, LVEF, NYHA class, and gender distribution grouped
by LVEF range is shown in Table 3. The mean DFT voltage for
LVEF  25% was 425.8+117.6 V, 26–35% was 417.5+121.1 V,
36–45% was 394.1+133.3 V, and  46% was 395.2+115 V
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Table 2 Patient population (n 5 230)
Age 66.6+12.4 years
Gender 81% males
NYHA class
I 12.6%
II 40%
III 25.2%
IV 1.3%
Unknown 20.9%
Ischaemia 74.3%
Implant indication
Primary 63%
Secondary 33%
Unknown 4%
Hypertension 54%
Amiodarone usage 9.1%
J.E. Val-Mejias and A. Oza 386(Table 3). Similarly, the mean DFT energies for LVEF  25% was
8.6+4.9 J, 26–35% was 8.4+5.1 J, 36–45% was 7.6+4.4 J,
and  46% was 7.5+4.2 J (Table 3). DFTs (voltage and energy)
trended higher for lower LVEF but this trend is not statistically sig-
niﬁcant (P ¼ 0.58 for DFT voltage and P ¼ 0.69 for DFT energy).
Only 3% of the patients (n ¼ 7) had a DFT of .20 J and all of
these high-DFT patients had an LVEF ,35% (Figure 1). Of these
seven high-DFT patients, a .10 J safety margin could not be
achieved in three patients.
All of the patients (n ¼ 7) with DFT . 20 J were men with an
LVEF   35%. In this group, ﬁve patients received an ICD/CRT-D
for primary prevention, four had ischemic cardiomyopathy, four
had hypertension, and four had undergone previous ablation for
sustained ventricular tachycardia. Two of these patients were
below the age of 50 years, three of them were between 50 and
65 years, and two were above 65 years of age. Similarly, each of
the patients (n ¼ 4) with DFT . 25 J had received an ICD/
CRT-D for primary prevention; two had ischaemic cardiomyopa-
thy and two had hypertension. One of the patients was younger
than 50 years, two were between 50 and 65 years, and one was
above 65 years.
A multiple variable regression estimation model constructed
to estimate the effect of age, gender, NYHA class, LVEF,
implant indication, type of study, and method of VF induction
on DFTs revealed that gender was the only signiﬁcant predictor
of higher DFTs in this patient population, with men having
higher DFTs than women (P ¼ 0.02). The mean DFT in men
was greater than that in women by 58.7 V (15.2%) and 2.3 J
(31.3%).
Discussion
This is the ﬁrst analysis that attempts to stratify the DFT estimates
by LVEF in patients tested with biphasic, tuned waveforms that are
optimized based on the high-voltage lead impedance. The primary
results indicate that both DFT voltage and energy increase as LVEF
decreases, but the difference in DFT energy between each adjacent
LVEF group is very small and, even between the highest and the
lowest LVEF groups is minimal (approximately 1 J).
In previous studies, the association of LVEF and DFT has been
inconsistent.
4,7,8,13–18 Burke et al.
13 analysed DFTs in 50 ICD/
CRT-D patients. Although the mean LVEF in CRT-D group was sig-
niﬁcantly lower than that of the ICD group (23+5% for the CRT
group vs. 31+10% for the control group), the mean DFTs of the
two groups were not signiﬁcantly different (10.2+6.1 J for the
CRT group vs. 9.5+5.0 J for the control group). Similarly, Cuoco
Jr. et al.
14 found no signiﬁcant difference in DFT between ICD and
CRT-D groups (n ¼ 537). In the ASSURE study,
15 Doshi et al.
showed that patients receiving CRT-D devices do not have higher
deﬁbrillation energy requirements when compared with ICD
patients. Val-Mejias et al.
16 found no difference in the DFTestimates
between ICD/CRT-D patients implanted with primary and second-
ary prevention indications, in spite of signiﬁcant differences in the
LVEF between the two indication groups. In an analysis of 128
patients who received Ventak ICDs, Horton et al.
17 did not ﬁnd
LVEF to be a signiﬁcant factor in predicting high DFT. However,
several studies have shown that LVEF was one of the signiﬁcant pre-
dictorsofahighDFT.Intheirreviewof1139patientrecordswithall
manufacturer’s devices, Russo et al.
18 found that 71 patients (6.2%)
...............................................................................................................................................................................
Table 3 Patient population and DFT estimates grouped by LVEF
LVEF range LVEF (%) Gender Age (years) NYHA class Impedance (V) DFT voltage (V) DFT energy (J)
 25% (n ¼ 102) 20.7+4.0 85% male 65+12.2 2.5+0.6 40.9+6.6 425.8+117.6 8.6+4.9
26–35% (n ¼ 90) 32.7+4.3 82% male 67+12.2 2.0+0.7 41.2+6.3 417.5+121.1 8.4+5.1
36–45% (n ¼ 17) 41.2+3.4 71% male 67+11.6 1.8+0.7 40.1+6.2 394.1+133.3 7.6+4.4
 46% (n ¼ 21) 54.9+5.2 62% male 74+12.4 1.3+0.6 40.5+5.2 395.2+115.0 7.5+4.2
P ¼ not signiﬁcant.
Figure 1 Distribution of DFT energies by different LVEF ranges.
Does deﬁbrillation threshold increase as LVEF decreases? 387had high DFTs (,10 J safety margin). Lower LVEF had a borderline
predictive value for the need for system revision owing to lack of a
10 J safety margin (P ¼ 0.054). Similarly, Shukla et al.
17 analysed 968
patients with Medtronic devices and found that patients with higher
threshold ( 18 J) had lower LVEF, a worse functional class, less
frequently done bypass surgery, amiodarone and history of more
frequent VF. Both Lubinski et al.
7 (n ¼ 168) and Pinski et al.
8 (n ¼
125) found that low LVEF was a signiﬁcant predictor of high
DFT.Inanolderstudyinvolving128patientswhoreceivedepicardial
deﬁbrillators, high LVEF was found to be an important determinant
of improved deﬁbrillation efﬁcacy.
4
In this study, only 7 of the 230 patients had a DFT . 20 J which is
slightly lower than the incidence reported in other studies that
employed ﬁxed tilt waveforms.
5–8,19,20 This could be because the
DFT protocol in some of these studies was neither uniform nor
wasitfollowedconsistentlyandthedeﬁnitionofhighDFTwasdiffer-
entfromthecurrentstudy.Interestingly,allthe‘highDFT’patientsin
our study had an LVEF of ,35% suggesting that the occurrence of
high DFT is not acommon problem in patients with normal to near-
normal LVEF. It should be noted that the results from the current
studywereobtainedwithﬁxedpulse-widthwaveformsthatareopti-
mally tuned per impedance and assumed cardiac membrane time
constant. Fixed pulse-width waveforms have been shown to
provide lower voltage and energy DFTs than ﬁxed-tilt waveforms,
particularly when DFT is higher than 400 V. This might explain our
lower DFT per LVEF range as well as our lower incidence of ‘high
DFT’.
21,22 It should be noted that concerns regarding DFTs
between 20 and 26 J may not be as great when a device with
maximum delivered energy capability of 36 J is used because a 10 J
safety margin would be available.
This analysis should be interpreted under the light of certain
limitations. First, this is a retrospective analysis, hence there is an
unequal number of patients in the four stratiﬁed LVEF groups.
Second, DFT estimates in all the patients were obtained with a left-
sided, active pectoral pulse generator that utilized biphasic, tuned
waveforms with SVC coil turned ON. We cannot assure that
similar results would be observed if the different waveforms, gen-
erator pocket location, shocking vector, or lead conﬁgurations are
used. In addition, the impact of inﬁltrative cardiomyopathy (i.e. sar-
coidosis, amyloidosis, etc.) could not be assessed because there
were no patients in the cohort with those diseases. The impact
of kidney disorders could not be evaluated because data reﬂecting
renal function was not collected in any of the three studies.
Conclusion
This analysis shows that across a very broad range of LVEF, changes
in DFT are minimal. No patient with a near-normal to preserved
LVEF had an occurrence of high DFT, and among the patients
with severely impaired LVEF only a few (3%) had high DFTs.
These results should reassure implanters that patients with
severely impaired LVEF implanted with left-sided ICD/CRT-D
devices employed with tuned deﬁbrillation waveforms and dual-
shocking leads will not necessarily have elevated DFTs.
Conﬂict of interest: J.E.V.-M. has received research support and
fellows program support from St. Jude Medical. A.O. is an
employee of and holds stock in St. Jude Medical.
Funding
The studies mentioned in this article were funded by St. Jude Medical.
Funding to pay the Open Access publication charges for this article was
provided by St. Jude Medical.
References
1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Improved
survival with an implantable deﬁbrillator in patients with coronary disease at
high risk for ventricular arrhythmia. N Engl J Med 1996;355:1933–40.
2. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Haﬂey G. A ran-
domized study of the prevention of sudden death in patients with coronary
artery disease. N Engl J Med 1999;341:1882–90.
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic
implantation of a deﬁbrillator in patients with myocardial infarction and reduced
ejection fraction. N Engl J Med 2002;346:877–83.
4. Shukla HH, Flaker GC, Jayam V, Roberts D. High deﬁbrillation thresholds in trans-
venous biphasic implantable deﬁbrillators: clinical predictors and prognostic impli-
cations. PACE 2003;26:44–8.
5. Leitch JW, Yee R. Predictors of deﬁbrillation efﬁcacy in patients undergoing epi-
cardial deﬁbrillator implantation: the multicenter Pacemaker-Cardioverter-
Deﬁbrillator (PCD) Investigators Group. J Am Coll Cardiol 1993;21:632–1637.
6. Raitt MH, Johnson G, Dolack GL, Poole JE, Kudenchuk PJ, Bardy GH. Clinical pre-
dictors of the deﬁbrillation threshold with the unipolar implantable deﬁbrillation
system. J Am Coll Cardiol 1995;25:1576–83.
7. Lubinski A, Lewicka-Nowak E, Zienciuk A, Krolak T, Kempa M, Pazdyga A et al.
Clinical predictors of deﬁbrillation threshold in patients with implantable
cardioverter-deﬁbrillators. Kardiol Pol 2005;62:317–28.
8. Pinski SL, Vanerio G, Castle LW, Morant VA, Simmons TW, Trohman RG et al.
Patients with a high deﬁbrillation threshold: clinical characteristics, management,
and outcome. Am Heart J 1991;122:89–95.
9. Natarajan S, Henthorn R, Burroughs J, Esberg D, Zweibel S, Ross T et al. Fixed
duration ‘tuned’ deﬁbrillation waveforms outperform ﬁxed 50/50% tilt deﬁbrilla-
tion waveforms: a randomized, prospective, pair-sampled multicenter study.
Pacing Clin Electrophysiol 2007;30:S139–S142.
10. Gold MR, Val-Mejias J, Leman RB, Tummala R, Goyal S, Kluger J et al. Optimization
of superior vena cava coil position and usage for transvenous deﬁbrillation. Heart
Rhythm 2008;5:394–9.
11. Doshi S, Val-Mejias JE, Pittaro M, Reeves R, Boyce K, Payne J et al. Efﬁcacy of tuned
waveforms based on different membrane time constants on deﬁbrillation
thresholds: primary results from the POWER trial. Europace 2008;10:i100.
12. ICD Alternative Deﬁbrillation Bi-phasic Waveform Pulse Width Recommendations Rev. 1.
Sylmar, CA: St Jude Medical CRMD.
13. Burke SW, Sturdivant LJ, Leman RB, Wharton MJ, Gold MR. Deﬁbrillation
thresholds in patients with cardiac resynchronization therapy deﬁbrillators.
Heart Rhythm 2006;3:S165.
14. Cuoco FA Jr, Leslie DL, Luff M, Maran A, Klein MH, Forcina MS et al. Elevated
deﬁbrillation threshold in CRT-D and ICD patients: comparison and predictors.
Heart Rhythm 2008;5:S237.
15. Doshi RN, Crandall BG, Osborn JS, Weiss P, Kfoury A, Wang S et al. Do biven-
tricular pacemaker deﬁbrillators patients have higher deﬁbrillation thresholds?
Heart Rhythm 2005;2:S243.
16. Val-Mejias JE, Gold M, Natarajan S, Oza A. Is there a difference in deﬁbrillation
thresholds between patients with primary vs. secondary prevention indications?
Europace Suppl 2007;9:iii186.
17. Horton RP, Canby RC, Roman CA, Hull ML, Kaye SA, Jessen ME et al. Determi-
nants of nothoractomy biphasic deﬁbrillation. PACE 1997;20:60–4.
18. Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM et al. Deﬁbrilla-
tion threshold testing: Is it really necessary at the time of implantable
cardioverter-deﬁbrillator insertion? Heart Rhythm 2005;2:456–61.
19. Schuger C, Ellenbogen KA, Faddis M, Knight BP, Yong P, Sample R. Deﬁbrillation
energy requirements in an ICD population receiving cardiac resynchronization
therapy. J Cardiac Electrophysiol 2006;17:247–50.
20. Mainigi SK, Cooper JM, Russo AM, Nayak HM, Lin D, Dixit S et al. Elevated deﬁ-
brillation thresholds in patients undergoing biventricular deﬁbrillator implantation:
incidence and predictors. Heart Rhythm 2006;3:1010–6.
21. Mouchawar G, Kroll MW, Val-Mejias JE, Schwartzman D, McKenzie J, Fitzgerald D
et al. ICD waveform optimization: a randomized, prospective, pair-sampled multi-
center study. PACE 2000;23:1992–5.
22. Denman RA, Umesan C, Martin PT, Forbes RN, Kroll MW, Anskey EJ et al. Beneﬁt
of millisecond waveform durations for patients with high deﬁbrillation thresholds.
Heart Rhythm 2006;3:536–41.
J.E. Val-Mejias and A. Oza 388